BioCentury
ARTICLE | Clinical News

Toctino alitretinoin: Development discontinued

February 22, 2016 8:00 AM UTC

GSK discontinued its Toctino U.S. program. Basilea, which granted GSK exclusive, worldwide rights to alitretinoin in 2012, has the option to reacquire U.S. rights. In 2015, Almirall S.A. (Madrid:ALM,...